DE60034954D1 - Substrate und screeningverfahren für transportproteine - Google Patents
Substrate und screeningverfahren für transportproteineInfo
- Publication number
- DE60034954D1 DE60034954D1 DE60034954T DE60034954T DE60034954D1 DE 60034954 D1 DE60034954 D1 DE 60034954D1 DE 60034954 T DE60034954 T DE 60034954T DE 60034954 T DE60034954 T DE 60034954T DE 60034954 D1 DE60034954 D1 DE 60034954D1
- Authority
- DE
- Germany
- Prior art keywords
- transport proteins
- methods
- substrate
- screening process
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15407199P | 1999-09-14 | 1999-09-14 | |
PCT/US2000/025439 WO2001020331A1 (en) | 1999-09-14 | 2000-09-14 | Substrates and screening methods for transport proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60034954D1 true DE60034954D1 (de) | 2007-07-05 |
Family
ID=22549879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60034954T Expired - Lifetime DE60034954D1 (de) | 1999-09-14 | 2000-09-14 | Substrate und screeningverfahren für transportproteine |
Country Status (6)
Country | Link |
---|---|
US (2) | US7413536B1 (de) |
EP (1) | EP1212619B1 (de) |
AT (1) | ATE363074T1 (de) |
AU (1) | AU7703400A (de) |
DE (1) | DE60034954D1 (de) |
WO (1) | WO2001020331A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1267898A4 (de) * | 2000-04-07 | 2006-02-01 | Univ Maryland | Gallensäure enthaltend propharmaka mit erhöhter bioavibilität |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
JP4342934B2 (ja) | 2001-06-11 | 2009-10-14 | キセノポート インコーポレーティッド | Pept−2輸送体を介した薬剤の投与 |
US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
WO2003070174A2 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
FR2840994B1 (fr) * | 2003-01-22 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
JP2005534000A (ja) | 2002-05-31 | 2005-11-10 | コミッサリア ア レネルジ アトミック | 放射性分子の群のスクリーニングの方法およびその使用 |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
WO2005075992A1 (en) * | 2004-01-30 | 2005-08-18 | Xenoport, Inc. | Mct1 transporter expressed in blood brain barrier cells |
BRPI0509732A (pt) * | 2004-04-09 | 2007-09-25 | Chugai Pharmaceutical Co Ltd | pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco |
WO2006017351A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
ATE410408T1 (de) | 2004-07-12 | 2008-10-15 | Xenoport Inc | Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
WO2007038659A1 (en) | 2005-09-26 | 2007-04-05 | Invitrogen Corporation | Violet laser excitable dyes and their method of use |
KR20080093036A (ko) * | 2006-01-31 | 2008-10-17 | 사노피-아벤티스 | 유기 양이온 수송체의 활성을 측정하는 방법 |
US7582417B2 (en) | 2006-02-17 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Sequential reporter enzyme luminescence (SRL) methods and compositions for practicing the same |
CA2649148C (en) | 2006-04-13 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Taurine transporter gene |
US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
AU2007333225B2 (en) * | 2006-12-08 | 2014-06-12 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
EP2135946B1 (de) | 2007-03-15 | 2015-12-09 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur polypeptidherstellung |
ES2591284T3 (es) | 2007-08-07 | 2016-11-25 | Chugai Seiyaku Kabushiki Kaisha | Método para la producción de proteínas heterogéneas |
EP2194126B1 (de) * | 2007-10-15 | 2014-01-15 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur konstruktion von zellen mit hoher produktivität von fremdprotein |
JP5337044B2 (ja) | 2007-10-24 | 2013-11-06 | 中外製薬株式会社 | 異種タンパク質製造のための細胞及びそれを用いた製造方法 |
EP2276479B1 (de) | 2008-04-15 | 2014-07-02 | SineVir Therapeutics LLC | Prodrugs von neuraminidasehemmern |
EP3653763A1 (de) | 2009-02-13 | 2020-05-20 | X-Chem, Inc. | Verfahren zur erstellung und durchsuchung von dna-codierten bibliotheken |
EP2396406A4 (de) * | 2009-02-13 | 2012-08-08 | X Body Inc | Identifizierung von vehikeln zur nukleinsäurefreisetzung mittels dna-anzeige |
JP5715050B2 (ja) | 2009-04-22 | 2015-05-07 | 中外製薬株式会社 | 異種タンパク質を高生産する細胞の作製方法 |
CA2768352C (en) * | 2009-07-16 | 2016-10-11 | Beckman Coulter, Inc. | Novel fluorescent dyes and uses thereof |
JP5561692B2 (ja) * | 2010-03-09 | 2014-07-30 | 国立大学法人群馬大学 | 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法 |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US8399262B2 (en) | 2011-03-23 | 2013-03-19 | Darrel A. Mazzari | Biosensor |
SG11201400374TA (en) | 2011-09-07 | 2014-09-26 | Chem Inc X | Methods for tagging dna-encoded libraries |
CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
CA2879018A1 (en) | 2012-07-13 | 2014-01-16 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
BR112015023697A2 (pt) | 2013-03-15 | 2017-07-18 | Lumena Pharmaceuticals Inc | inibidores de ácidos biliares de reciclagem para tratamento de esôfago de barrett e doença do refluxo gastroesofágico |
JP2016514684A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 |
CA3007635A1 (en) | 2015-12-07 | 2017-06-15 | Zymergen Inc. | Promoters from corynebacterium glutamicum |
US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
EP3478833A4 (de) | 2016-06-30 | 2019-10-02 | Zymergen, Inc. | Verfahren zum erzeugen einer bakteriellen hämoglobin-bibliothek und deren verwendung |
JP2019519241A (ja) | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | グルコース透過酵素ライブラリーを生成するための方法およびその使用 |
GB2552460A (en) | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
EP4245367A3 (de) | 2019-02-12 | 2023-12-20 | Mirum Pharmaceuticals, Inc. | Verfahren zur behandlung von cholestase |
WO2021023100A1 (zh) * | 2019-08-06 | 2021-02-11 | 杜心赟 | 脱氧胆酸类化合物、药物组合物及其用途 |
EP4049032A1 (de) | 2019-10-25 | 2022-08-31 | Cercacor Laboratories, Inc. | Indikatorverbindungen, vorrichtungen, die indikatorverbindungen umfassen, und verfahren zur herstellung und verwendung derselben |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5569678A (en) * | 1989-07-31 | 1996-10-29 | Massachusetts Institute Of Technology | Control of wound scar production |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
US5866123A (en) * | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
US5236902A (en) * | 1990-11-26 | 1993-08-17 | The Governors Of The University Of Alberta | Method and probes for detecting nucleoside transporter and method for producing the probes |
US5580775A (en) | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
DE4222315A1 (de) * | 1992-07-05 | 1994-01-13 | Inst Genbiologische Forschung | DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
US5658782A (en) * | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
DE4343527A1 (de) * | 1993-12-16 | 1995-06-22 | Schering Ag | Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung |
US5589358A (en) | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
US5750788A (en) * | 1994-11-12 | 1998-05-12 | Basf Aktiengesellschaft | Preparation of amines from compounds having at least 3 cyano groups |
JPH11504218A (ja) * | 1995-04-24 | 1999-04-20 | クロマゾーム コーポレーション | 新規代謝経路の生成およびスクリーニングのための方法 |
EP0876611A1 (de) | 1995-09-11 | 1998-11-11 | La Jolla Cancer Research Foundation | Moleküle die sich in ausgewählten organen oder geweben in-vivo einfinden und verfahren zu ihrer identifizierung |
CA2234685A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US5780264A (en) | 1996-06-06 | 1998-07-14 | The President And Fellows Of Harvard College | Iron transport protein |
WO1998002451A1 (en) * | 1996-07-16 | 1998-01-22 | Novo Nordisk A/S | Oligopeptide transporters |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
AU730100B2 (en) * | 1997-02-27 | 2001-02-22 | Cellomics, Inc. | A system for cell-based screening |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
NZ501110A (en) * | 1997-05-15 | 2001-10-26 | Elan Corp Plc | Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related drug delivery methods |
WO1999003823A2 (en) | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
-
2000
- 2000-09-14 AT AT00966735T patent/ATE363074T1/de not_active IP Right Cessation
- 2000-09-14 DE DE60034954T patent/DE60034954D1/de not_active Expired - Lifetime
- 2000-09-14 AU AU77034/00A patent/AU7703400A/en not_active Abandoned
- 2000-09-14 US US09/661,927 patent/US7413536B1/en not_active Expired - Fee Related
- 2000-09-14 EP EP00966735A patent/EP1212619B1/de not_active Expired - Lifetime
- 2000-09-14 WO PCT/US2000/025439 patent/WO2001020331A1/en active IP Right Grant
-
2008
- 2008-07-14 US US12/172,801 patent/US20090221442A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7413536B1 (en) | 2008-08-19 |
AU7703400A (en) | 2001-04-17 |
ATE363074T1 (de) | 2007-06-15 |
EP1212619B1 (de) | 2007-05-23 |
WO2001020331A1 (en) | 2001-03-22 |
US20090221442A1 (en) | 2009-09-03 |
WO2001020331A9 (en) | 2002-10-03 |
EP1212619A4 (de) | 2004-12-08 |
EP1212619A1 (de) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60034954D1 (de) | Substrate und screeningverfahren für transportproteine | |
DE60232688D1 (de) | Grenzflächen-biomaterialien | |
AU6380001A (en) | Porous ferro- or ferrimagnetic glass particles for isolating molecules | |
DE60017945D1 (de) | Verfahren zur kryokonservierung von samenzellen | |
DE69433564D1 (de) | Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung | |
DK1141137T3 (da) | Vandopløselige rhodaminfarvestoffer og konjugater deraf | |
WO2007120699A3 (en) | Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals | |
DK0922102T3 (da) | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf | |
EP1379693A4 (de) | Auf oligonukleotid-modifizierten partikeln basierende bio-strichcodes | |
ATE295347T1 (de) | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen | |
DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
WO2004055519A3 (en) | Specific markers for pancreatic cancer | |
ATE352784T1 (de) | Verfahren zum screenen für gpr40-liganden | |
ATE405841T1 (de) | In-vitro-verfahren zum gleichzeitigen nachweisen und identifizieren von antibiotika unterschiedlicher klassen sowie entsprechender diagnostischer kit | |
DE69925032D1 (de) | Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening | |
ATE541046T1 (de) | Verfahren zur entkopplung des reaktionsmassstabs und der proteinsyntheseausbeute im diskontinuierlichen modus | |
DE69912839D1 (de) | Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung | |
DE59806371D1 (de) | Kontrastmittel für das infarkt- und nekroseimaging | |
WO1999050459A3 (en) | High throughput in vitro screening assays for transcription modulators | |
RS20100249A (en) | CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE | |
MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
WO2003008635A8 (en) | η-SECRETASE IN VITRO SCREENING ASSAY | |
ATE252574T1 (de) | Benzofuran-2-ones als färbemittel für organische materialien | |
DE69913533D1 (de) | Reagentien für cyp2d fluoreszenztest | |
ATE501274T1 (de) | Cucurbiturilderivat-gebundenes feststoffsubstrat und biochip unter verwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |